Description

Titan Biotech Ltd announces sub-division of equity shares from Rs.10/- each into five equity shares of Rs.2/- each, with record date of February 20, 2026.

Summary

BSE has notified that Titan Biotech Ltd (Scrip Code: 524717) will undergo a sub-division of its equity shares. Each existing equity share with a face value of Rs.10/- will be split into five equity shares with a face value of Rs.2/- each. The record date for this corporate action is February 20, 2026, and the new share structure will be effective from the same date.

Key Points

  • Company: Titan Biotech Ltd (Scrip Code: 524717)
  • Corporate Action: Sub-division of equity shares
  • Sub-division Ratio: 1:5 (One share of Rs.10/- into five shares of Rs.2/-)
  • Record Date: February 20, 2026
  • Effective Date: February 20, 2026
  • Old ISIN (INE150C01011) for Rs.10/- shares will become invalid for exchange transactions from February 20, 2026
  • New ISIN for Rs.2/- shares will be communicated via separate notice
  • Notice Reference: DR-825/2025-2026
  • Issued by: Marian Dsouza, Assistant Vice President – Listing Compliance & Operations

Regulatory Changes

No regulatory framework changes. This is a standard corporate action permitted under existing regulations where a company subdivides its shares to improve liquidity and affordability.

Compliance Requirements

  • Trading members must note the record date of February 20, 2026
  • The existing ISIN No. INE150C01011 (Rs.10/- paid-up) will not be valid for transactions on or after February 20, 2026
  • Market participants must update their systems to reflect the new ISIN once notified
  • Demat accounts will be automatically credited with subdivided shares
  • All references to share capital and shareholding must be adjusted to reflect the 1:5 split

Important Dates

  • January 21, 2026: Notice issued by BSE
  • February 20, 2026: Record date for sub-division
  • February 20, 2026: Effective date - new Rs.2/- shares become valid for trading
  • February 20, 2026: Old ISIN (INE150C01011) becomes invalid for exchange transactions

Impact Assessment

Market Impact: The sub-division will reduce the per-share price of Titan Biotech to one-fifth of the current price, potentially improving liquidity and making shares more accessible to retail investors. Outstanding shares will increase five-fold while market capitalization remains unchanged.

Operational Impact: Shareholders will automatically receive four additional shares for every one share held as of the record date. This affects portfolio accounting, holding statements, and all share-related calculations. The ISIN change requires system updates across depositories, trading platforms, and custodian systems.

Investor Impact: Existing shareholders face no dilution - their proportionate ownership remains unchanged. However, they must track the ISIN change and verify correct credit of subdivided shares in their demat accounts post-record date.

Impact Justification

Stock sub-division affects share price and liquidity but is a routine corporate action. Impacts all shareholders of Titan Biotech with ISIN changes requiring tracking.